San Antonio Breast Cancer Symposium
Lessons from the Phase III ZEST trial could inform ongoing and future trials as they seek to use ctDNA to prove efficacy of novel adjuvant treatments.
Data from Myriad Genetics offered early validation evidence for an expanded version of its commercial test, as well as a look into clinical impact via claims data.
Oncologists said the five-year outcomes data aren't enough to change standard of care but could inform conversations between patients and their doctors.
The company has faced some early hurdles in joining competitors in the colorectal cancer space but believes it can claim first mover status in early breast cancer.
Myriad Genetics Generates More Data on Ability of PRS to Identify Who Will Develop Breast Cancer
Premium
In a validation study presented at SABCS, Myriad evaluated how well breast cancer risk assessments made with a clinco-genomic risk score aligned with observed incidence.